Article - 22/12/2014 Bioinformaticians shed light into the data jungle In recent years, the University of Tübingen has developed a tightly integrated service structure for the computer-based management of life sciences data. This structure is the point of contact for all those that produce or work with “omics” data – in Tübingen and beyond.https://www.gesundheitsindustrie-bw.de/en/article/news/bioinformaticians-shed-light-into-the-data-jungle
Article - 22/12/2014 Fighting hepatitis viruses with their own weapons Virologist Prof. Dr. Stephan Urban from the University of Heidelberg has been awarded the DZIF Prize for Translational Infection Research for the discovery and development of a promising peptide drug for the treatment of hepatitis B virus infections. The peptide prevents viruses from entering the liver cells, and is also effective against hepatitis D infection. Hepatitis D is the deadliest of all viral liver diseases and no specific antiviral…https://www.gesundheitsindustrie-bw.de/en/article/news/fighting-hepatitis-viruses-with-their-own-weapons
Article - 22/12/2014 Large-scale urology project: cell therapy for the treatment of stress incontinence The first and so far only clinical DFG research group on urology is being coordinated by a team from Tübingen. The team is developing a cell-based therapy for the regeneration of the urethral sphincter. Clinicians, life scientists and engineers are working together to try and find a causal therapy of stress incontinence. https://www.gesundheitsindustrie-bw.de/en/article/news/large-scale-urology-project-cell-therapy-for-the-treatment-of-stress-incontinence
Article - 22/12/2014 The immune system – both weak and overreactive in the absence of CTLA4 The ability to recognise a pathogen and combat it effectively is certainly one of the most complex and sophisticated processes the human body has evolved. People with an immunodeficiency or autoimmune disease may have a genetic defect in one of the genes involved in the immune response. Working with immunologists from London scientists Desire Schubert and Prof. Dr. Bodo Grimbacher from the Centre for Chronic Immunodeficiency CCI at the Freiburg…https://www.gesundheitsindustrie-bw.de/en/article/news/the-immune-system-both-weak-and-overreactive-in-the-absence-of-ctla4
Article - 15/12/2014 From HIV structure to new AIDS therapies The building blocks of the viral protein capsid are rearranged as HI viruses mature into infectious AIDS-causing agents. Researchers from Heidelberg have made these structural changes visible on the molecular level. The findings could potentially be used for developing much-needed new AIDS therapeutics.https://www.gesundheitsindustrie-bw.de/en/article/news/from-hiv-structure-to-new-aids-therapies
Article - 15/12/2014 Heart muscle cell 1.0 and 2.0 – two epigenetic programmes in one cell All the cells in an organism have to adapt to changing requirements as they develop and grow - including muscle cells in the heart. Crucial to this process are the cells’ growth in size and epigenetic factors that play a role in modulating the expression of various genes. The role of epigenetics in cancer development has been the focus of research for quite some time. The question is, what role do epigenetic factors play in the development of the…https://www.gesundheitsindustrie-bw.de/en/article/news/heart-muscle-cell-1-0-and-2-0-two-epigenetic-programmes-in-one-cell
Article - 08/12/2014 Stefan Hell – a Nobel Prize for a lateral thinker Stefan Hell was awarded the Nobel Prize in Chemistry for the development of STED fluorescence microscopy which has made it possible to obtain optical images well below the optical diffraction limit. However, Hell does not really see himself as a developer. His passion is scientific principles, the identification of how things are connected and the exploration of new, uncharted paths.https://www.gesundheitsindustrie-bw.de/en/article/news/stefan-hell-a-nobel-prize-for-a-lateral-thinker
Article - 01/12/2014 Stem cell research for preventing radiation-induced developmental damage Although ionizing radiation is known to cause cell damage and genetic modifications, its effects on embryonic development are still poorly understood. This is why Prof. Dr. Suzanne Kadereit from the Albstadt-Sigmaringen University of Applied Sciences is involved in a cooperative project that uses human embryonic stem cells for studying the effects of ionizing radiation on prenatal brain development. She heads up the only university of applied…https://www.gesundheitsindustrie-bw.de/en/article/news/stem-cell-research-for-preventing-radiation-induced-developmental-damage
Article - 28/11/2014 Martin Plenio - turning Ulm’s quantum biology into a technology forge Quantum biology has the potential to become the next big research coup. Professor Martin Plenio, 46, director of the Institute of Theoretical Physics at Ulm University and one of the world’s leading quantum technologists, is right at the forefront. He has been Alexander von Humboldt Professor since 2009, and holds a part-time professorship at Imperial College London, where he was formerly chair of quantum physics.https://www.gesundheitsindustrie-bw.de/en/article/news/martin-plenio-turning-ulm-s-quantum-biology-into-a-technology-forge
Press release - 26/11/2014 Curetis Closes EUR 14.5 Million Extension of Series B Financing Curetis AG wins new investors QIAGEN and LSP-HEF, committing EUR 7 million. Hence Curetis is well financed into 2017. Curetis AG, a developer of next-level molecular diagnostic solutions, today announced it has closed a EUR 14.5 million extension of its Series B financing round, which was originally led by HBM Partners in April 2013.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-closes-eur-14-5-million-extension-of-series-b-financing
Article - 24/11/2014 Lipid zipper triggers bacterial invasion Millions of people die each year from infections both in developing and industrial countries. There is still no effective treatment for a large number of diseases caused by pathogens. In order to treat infectious diseases effectively, we need to understand the mechanisms that bacteria use to infect human cells. The cytoskeleton of the host cell usually plays a key role in this process. Researchers at the University of Freiburg have discovered a…https://www.gesundheitsindustrie-bw.de/en/article/news/lipid-zipper-triggers-bacterial-invasion
Article - 17/11/2014 About synapses and learning You can’t teach an old dog new tricks – the old proverb is not totally true. It is now known that the modulation of synaptic functions, including the formation of new neurons, still takes place in old age, although to a lesser extent than in childhood. The human brain stores memories in the form of neural activity patterns. Structural plasticity appears to be the basis for all learning processes. Physician Thomas Hainmüller and Prof. Dr. Marlene…https://www.gesundheitsindustrie-bw.de/en/article/news/about-synapses-and-learning
Guest article - 10/11/2014 Six Months Research in an Incredible City at the other Side of the World The fellowship program “Research stay for application-oriented bioscientists and biotechnologists in Shanghai and Jiangsu/China” funded by the Baden-Württemberg Ministry of Science, Research and the Arts enabled Sonja Blasche to spend six months at the Minhang Campus of the Jiao Tong University in Shanghai. During this time she worked in the laboratory of Professor Zhao Liping, an internationally known expert on microbial communities and the…https://www.gesundheitsindustrie-bw.de/en/article/news/six-months-research-in-an-incredible-city-at-the-other-side-of-the-world
Dossier - 10/11/2014 Cell and gene therapies: from bench to bedside While cell therapy has become standard treatment for a number of blood cancers, most cell and gene therapy approaches for the treatment of hereditary and metabolic diseases, neurodegenerative disorders and cancer are still in the experimental phases or early clinical trials. However, recent successes give rise to the hope that cell and gene therapies will in future make important contributions to previously incurable diseases.https://www.gesundheitsindustrie-bw.de/en/article/dossier/cell-and-gene-therapies-from-bench-to-bedside
Article - 10/11/2014 Alzheimer: amyloid-beta triggers mitochondrial dysfunction Neurons are very sensitive to disturbances and many different functions are no longer able to work efficiently when the power supply is impaired. Prof. Dr. Chris Meisinger and his team at the Institute of Biochemistry and Molecular Biology at the University of Freiburg have found that amyloid-beta peptides block important enzymes in the mitochondria resulting in mitochondrial dysfunction.https://www.gesundheitsindustrie-bw.de/en/article/news/alzheimer-amyloid-beta-triggers-mitochondrial-dysfunction
Press release - 05/11/2014 Orphan drug status for Synovo's immune modulator SYD003 The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to Synovo's investigational compound SYD003, a first in class tumour-targeted immune modulator.https://www.gesundheitsindustrie-bw.de/en/article/press-release/orphan-drug-status-for-synovo-s-immune-modulator-syd003
Article - 03/11/2014 Dementia and the prion principle Prions are misfolded proteins that are associated with diseases such as BSE, Creutzfeldt-Jakob disease and scrapie. What makes prions particularly dangerous is their ability to induce properly folded proteins to convert into misfolded prion forms. This principle seems to be more widespread than previously thought. Dr. Mathias Jucker from the University of Tübingen and his American colleague Lary Walker from Emory University have put forward a…https://www.gesundheitsindustrie-bw.de/en/article/news/dementia-and-the-prion-principle
Article - 27/10/2014 Takeda GmbH in Singen – pharmaceutical development and production under one roof From stomach protection agents to drugs for the treatment of respiratory distress in preterm infants – Singen-based Takeda GmbH plays an important role as a competence centre for drugs in liquid and semi-solid dosage form within the Japanese pharmaceutical company’s global network. Besides the production of around 68 million packages per year, the company’s production site in Singen also focuses on drug development. The company’s CMC Centre…https://www.gesundheitsindustrie-bw.de/en/article/news/takeda-gmbh-in-singen-pharmaceutical-development-and-production-under-one-roof
Article - 20/10/2014 QIAGEN Lake Constance – pocket-sized laboratories for the efficient identification of pathogens Quick, simple and decentralized – this is how QIAGEN Lake Constance GmbH envisages diagnostics applications in the future. The Stockach-based QIAGEN subsidiary develops test systems for point-of-need diagnostics, i.e. tests that can be carried out in close proximity to the sample collection point, for example in GP surgeries. They enable the rapid identification of pathogens, and as a result the timely initiation of suitable treatment.https://www.gesundheitsindustrie-bw.de/en/article/news/qiagen-lake-constance-pocket-sized-laboratories-for-the-efficient-identification-of-pathogens
Article - 20/10/2014 First ever eye gene therapy close to clinical testing There are many different retinal diseases simply because many different steps of the visual process can be affected. However, they all have one thing in common: correction of the relevant defective gene currently provides the only possibility of permanent cure. Prof. Dr. Mathias Seeliger and his group of researchers at the Institute of Ophthalmic Research at the University Hospital in Tübingen is specifically focused on the development of gene…https://www.gesundheitsindustrie-bw.de/en/article/news/first-ever-eye-gene-therapy-close-to-clinical-testing
Article - 20/10/2014 Michael Schindler: HI virus and host interactions Prof. Dr. Michael Schindler explores the interaction between viruses and their human host cells on the molecular level. His specific interest is HI virus infections and the mechanisms the virus uses to attack the human immune system. Schindler’s eventual aim is to identify a new target for the therapy of HIV infections. In April 2014, Schindler was appointed head of the Department of Molecular Virology of Human Infectious Diseases at the…https://www.gesundheitsindustrie-bw.de/en/article/news/michael-schindler-hi-virus-and-host-interactions
Article - 13/10/2014 Concepts for breaking the smoking habit Giving up smoking would mean an estimated 30 percent reduction in cardiovascular disease and a 90 percent reduction in cases of lung cancer, and that’s just in men. There are many arguments for giving up smoking. However, despite being highly motivated, many smokers fail to do so. Professional help is therefore available in the form of behavioural- and pharmacotherapy. The relevant guidelines in Germany have just been amended and now recommend a…https://www.gesundheitsindustrie-bw.de/en/article/news/concepts-for-breaking-the-smoking-habit
Article - 13/10/2014 Personalised cancer therapy based on microRNA analysis microRNAs are not just required for the regulation of gene expression, their expression signatures also allow conclusions to be drawn on the type and progression of cancer. Sensovation AG is therefore working with partners from industry and clinical research to develop an automated microRNA analysis platform that can detect and evaluate microRNA signatures faster than has previously been possible. The system is designed to make it easier to…https://www.gesundheitsindustrie-bw.de/en/article/news/personalised-cancer-therapy-based-on-microrna-analysis
Article - 13/10/2014 Data mining is likely to play an increasing role in clinical development Data mining still plays a minor role in the research-based pharmaceutical industry. But this is likely to change in the future. Mathematician Hans-Jürgen Lomp predicts that exploratory data analysis will be used to a greater extent in the future. Lomp is the Global Head of Statistics in Boehringer Ingelheim Pharma GmbH & Co KG’s Department of Medical Data Service and Biostatistics in Biberach.https://www.gesundheitsindustrie-bw.de/en/article/news/data-mining-is-likely-to-play-an-increasing-role-in-clinical-development
Press release - 09/10/2014 Stefan Hell - Nobel Prize in Chemistry For the second time a researcher at the DKFZ has been awarded the highest distinction in science: Professor Stefan Hell, director of the Max-Planck Institute for Biophysical Chemistry in Göttingen and department head at the DKFZ, has been awarded this year´s Nobel Prize in Chemistry for his pioneering work in the field of ultra high resolution fluorescence microscopy. This follows the 2008 Nobel Prize in Medicine for Harald zur Hausen.https://www.gesundheitsindustrie-bw.de/en/article/press-release/stefan-hell-nobel-prize-in-chemistry
Part 2 - 06/10/2014 Expert interview: How are the prices of innovative diagnostic and medical devices determined? While there are specific regulations in Germany for the reimbursement of medicines, funding for molecular diagnostics products is complex and virtually non-existent. There is hardly any medical insurance cover for medical devices, which therefore tend to be sold on the open market. The question therefore arises as to how a reasonable price can be determined for innovative diagnostic methods and tools. In the second part of the interview conducted…https://www.gesundheitsindustrie-bw.de/en/article/news/expert-interview-how-are-the-prices-of-innovative-diagnostic-and-medical-devices-determined
Article - 29/09/2014 myPOLS Biotec UG - made-to-measure enzymes for diagnostics and research The company myPOLS Biotec UG, a spin-off from the University of Konstanz, specializes in services involving DNA and RNA polymerases and creates artificial enzymes by evolution in test tubes. These next-generation polymerases can be used for many research and diagnostics applications. myPOLS Biotec’s polymerases are promising enzymes for future applications with the potential to make the detection of pathogens and DNA analysis faster and easier. https://www.gesundheitsindustrie-bw.de/en/article/news/mypols-biotec-ug-made-to-measure-enzymes-for-diagnostics-and-research
Article - 29/09/2014 Andrei Lupas – fascination for the complex world of proteins Prof. Dr. Andrei Lupas is a molecular biologist and director of the Department of Protein Evolution at the Max Planck Institute (MPI) for Developmental Biology in Tübingen. He became fascinated by the incredible complexity of proteins early on during his scientific career. His work focuses on the use of laboratory and computational methods to solve the question as to how a simple amino acid chain becomes a protein ‘nanomachine’. Lupas and his…https://www.gesundheitsindustrie-bw.de/en/article/news/andrei-lupas-fascination-for-the-complex-world-of-proteins
Guest article - 22/09/2014 Experience report: Six months Shanghai Sebastian Giese, a doctoral student at the University of Freiburg, spent six months in Shanghai with funding from a Baden-Württemberg Ministry of Science, Research and the Arts China scholarship. Below, Sebastian tells us about his impressions of the country and its people and his experiences in the megacity.https://www.gesundheitsindustrie-bw.de/en/article/news/experience-report-six-months-shanghai
Part 1 - 22/09/2014 Expert interview: How are the prices of new pharmaceuticals determined? Healthcare in Germany is quite good. Pharmaceutical and biotechnology companies carry out research in order to improve it further. The question is, how can a fair price for innovative drugs be determined? BIOPRO Baden-Württemberg GmbH has talked to Dr. Manfred Caeser, a specialist in pricing and reimbursement at LSCN Ltd.https://www.gesundheitsindustrie-bw.de/en/article/news/expert-interview-how-are-the-prices-of-new-pharmaceuticals-determined
Article - 15/09/2014 Mesenchymal stromal cells: promising cell therapy candidates Mesenchymal stromal cells MSC are increasingly moving into the spotlight as the beacon of hope for somatic cell therapies. The biomedical research community is currently carrying out more than 300 clinical trials to investigate their suitability for a broad range of indications. Prof. Schrezenmeier professor of transfusion medicine and medical director at the Institute for Clinical Transfusion Medicine and Immunogenetics IKT in Ulm is involved in…https://www.gesundheitsindustrie-bw.de/en/article/news/mesenchymal-stromal-cells-promising-cell-therapy-candidates
Article - 15/09/2014 Gene therapies for pulmonary disease are close to final development Gene therapy currently offers the only chance of curing genetic diseases such as cystic fibrosis and beta thalassaemia. Gene therapy is the replacement or correction of a mutated gene with DNA that encodes a functional gene. Intensive research has been going on in this field for many years however only a handful gene therapies are available at this point in time. Dr. Michael Kormann junior professor at the Childrens Hospital at the University of…https://www.gesundheitsindustrie-bw.de/en/article/news/gene-therapies-for-pulmonary-disease-are-close-to-final-development
Article - 08/09/2014 Thomas Boehm – pushing back the frontiers of knowledge The comparison of different animal species enables us to understand the crucial principle of immune defence on condition that the right investigative approach is chosen. Prof. Dr. Thomas Boehm director of the Max Planck Institute of Immunobiology and Epigenetics in Freiburg has been doing just this for many years. Based on insights into fundamental immune system functions Boehms research is aimed at developing new strategies for the diagnosis…https://www.gesundheitsindustrie-bw.de/en/article/news/thomas-boehm-pushing-back-the-frontiers-of-knowledge
Article - 08/09/2014 Molecular effects of traumatic stress After a traumatic experience, people often suffer not only mental, but also physical effects. Dr. María Moreno-Villanueva from the University of Konstanz has investigated the molecular effects of traumatic stress in people and has found a higher than normal number of DNA strand breaks. In the worst cases this can lead to diseases such as cancer. However, her study also shows that successful psychotherapy can reverse DNA damage. Her findings will…https://www.gesundheitsindustrie-bw.de/en/article/news/molecular-effects-of-traumatic-stress
Guest article - 01/09/2014 Nina Denneler’s review of her stay in Nanjing Nina Denneler spent six months in the Chinese province of Jiangsu, with funding from a special China scholarship from the Baden-Württemberg Ministry of Science, Research and the Arts. The 24-year-old is a student in the Department of Technical Biology at the University of Stuttgart and was able to experience the atmosphere of a Chinese lab at the College of Biotechnology and Pharmaceutical Engineering as well as gain interesting insights about…https://www.gesundheitsindustrie-bw.de/en/article/news/nina-denneler-s-review-of-her-stay-in-nanjing
Article - 01/09/2014 BARK CLOTH_europe – success through saving resources Ecological, economical and socially sustainable - all apply to a company called BARK CLOTH_europe, which in 2013 was one of 10 companies recognised as fabric innovators by the 'LAUNCH System Challenge: Fabric'. With its biomaterial made from the bark of the African Ficus tree, the company sells an innovative material that is produced using traditional methods.https://www.gesundheitsindustrie-bw.de/en/article/news/bark-cloth-europe-success-through-saving-resources
Article - 25/08/2014 Frederik Wenz - radiologist sets milestone with new surgical technique for the treatment of bone metastases Can painful bone metastases be treated in a targeted and quick way? Can metastases that are potentially present in the liver and kidneys be adequately treated at the same time as bone metastases? These are the questions that Professor Dr. med. Frederik Wenz from the University Medical Center Mannheim asked himself before going on to develop an innovative surgical technique. After a long development period, this technique is now recognized as an…https://www.gesundheitsindustrie-bw.de/en/article/news/frederik-wenz-radiologist-sets-milestone-with-new-surgical-technique-for-the-treatment-of-bone-metas
Press release - 20/08/2014 uniQure acquires HAE Accelerator Winner InoCard GmbH Heidelberg start-up develops gene therapy for the treatment of cardiac insufficiency. UniQure N.V. pays 3 million euros in cash and shares for the acquisition additional milestone payments and future revenue shares were agreed upon. https://www.gesundheitsindustrie-bw.de/en/article/press-release/uniqure-acquires-hae-accelerator-winner-inocard-gmbh
Article - 18/08/2014 The use of human genes as medical products In contrast to medications used for treating disease, gene therapy does not use chemical agents to alleviate or cure disease symptoms. Instead, it involves the introduction of a normal copy of a mutated gene to restore the function of a protein. Gene therapy could also be described as a way of restoring the body’s self-healing process. It is an extremely smart idea that enables the sustainable treatment of diseases which cannot usually be…https://www.gesundheitsindustrie-bw.de/en/article/news/the-use-of-human-genes-as-medical-products
Press release - 18/08/2014 Research Programme Bio-Economy: 11 projects at the University Stuttgart The use of sustainable raw materials is the focus of the new research programme bio-economy for which the Baden-Württemberg State Government is making 13 million Euros available. Of the total of 45 research projects recommended for funding 11 projects already approved are established at seven institutes at the University of Stuttgart these have a volume of two million Euros.https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-programme-bio-economy-11-projects-at-the-university-stuttgart
Article - 18/08/2014 Biometry: Peter Martus works at the interface of mathematics and medicine It’s not computer science, but it’s close to data: Prof. Dr. Peter Martus has an in-depth knowledge of how professional biotechnology and medical statistics are generated. Prof. Martus works at the University of Tübingen where he brings his know-how to clinical trials as well as working on life sciences projects where statistical issues need to be resolved.https://www.gesundheitsindustrie-bw.de/en/article/news/biometry-peter-martus-works-at-the-interface-of-mathematics-and-medicine
Article - 18/08/2014 VAXIMM: Vaccines that impede cancer growth VAXIMM GmbH, a young biotechnology company from Mannheim, Germany, specialises in the development of vaccines for cancer treatment. The company’s first product candidate, VXM01, is a live oral vaccine that targets the VEGFR-2 receptor and hence the blood supply of tumours. VXM01 is currently undergoing clinical testing in pancreatic cancer patients.https://www.gesundheitsindustrie-bw.de/en/article/news/vaximm-vaccines-that-impede-cancer-growth
Article - 11/08/2014 PRONTO develops microsystems for and with companies Since 2010, PRONTO, a project run by the MicroTEC Südwest cluster, has been focusing on the production of innovative microsystems for application in the medical and other sectors. PRONTO provides microsystems development support up to small-scale production. Customers who are seeking to implement their ideas into concrete microsystems solutions can count on the expertise and infrastructure of four institutes.https://www.gesundheitsindustrie-bw.de/en/article/news/pronto-develops-microsystems-for-and-with-companies
Article - 11/08/2014 dsl-Labor: developing PCR tests for medical diagnostics PCR has become a common application in medical diagnostics, in areas ranging from the detection of microbes to genetic testing. The demand for new tests is huge, given that there is a seemingly endless list of applications for which PCR can be used. dsl-Labor für Molekulargenetische Diagnostik specialises in the development of PCR tests and also gives advice and training to medical laboratory personnel. Veterinarians are among the company’s major…https://www.gesundheitsindustrie-bw.de/en/article/news/dsl-labor-developing-pcr-tests-for-medical-diagnostics
Article - 04/08/2014 A “growing” nail for lengthening bones The lengthening of a bone following a complicated fracture or as a result of the congenital shortening of the leg can help avoid problems that may occur in the future. The use of intramedullary nails to enable the gradual extension of the affected bone has become standard treatment. Prof. Dr.-Ing. Dr. h.c. Paul Gümpel’s group of researchers at the Konstanz University of Applied Sciences (HTWG) has developed an intramedullary nail made of a…https://www.gesundheitsindustrie-bw.de/en/article/news/a-growing-nail-for-lengthening-bones
Article - 04/08/2014 Europe’s first gene therapy Scientists from the National Center for Tumour Diseases (NCT) have shown that adeno-associated viruses (AAV) do not pose a cancer risk. This conclusion is based on the analysis of several million patient cells treated with AAV and the finding that the viruses do not integrate into the patient genome. AAV is the first-ever gene therapy for clinical use in the Western world. AAV vectors could also potentially be used as prototypes for the treatment…https://www.gesundheitsindustrie-bw.de/en/article/news/europe-s-first-gene-therapy
Article - 28/07/2014 Successes and setbacks of clinical gene therapy The use of retroviral haematopoietic stem cell gene therapy to treat hereditary immunodeficiencies has achieved great success in resolving the actual symptoms of the disease, but many of the patients that underwent therapy developed leukaemia later. Effective gene therapies involving gene shuttles that do not cause cancer are therefore required. The good news is that such therapies already exist.https://www.gesundheitsindustrie-bw.de/en/article/news/successes-and-setbacks-of-clinical-gene-therapy
Guest article - 21/07/2014 China - experiencing something new every single day The Baden-Württemberg Ministry of Science, Research and the Arts finances a scholarship scheme called “Research stay for application-oriented bioscientists and biotechnologists in Shanghai and Jiangsu/China”. A recent winner of this scholarship, Felix Wertek, spent six months at the Chinese Academy of Science in Shanghai and collected first-hand impressions of Chinese laboratory practice. Here, Felix reports about his exciting time in the Chinese…https://www.gesundheitsindustrie-bw.de/en/article/news/china-experiencing-something-new-every-single-day
Article - 21/07/2014 Predicting the efficiency of cancer drugs using mathematical models A research consortium was established at the Stuttgart Research Center Systems Biology SRCSB at the University of Stuttgart in January 2013 with the goal of establishing models that help predict the action of targeted therapeutics. The scientists combine molecular biology experiments with complex mathematical models in order to achieve a holistic understanding of disease and therapy. https://www.gesundheitsindustrie-bw.de/en/article/news/predicting-the-efficiency-of-cancer-drugs-using-mathematical-models